SPINK1基因突变与特发性慢性胰腺炎研究进展  

Update on the relationship between the SPINK1 mutation and the idiopathic chronic pancreatitis

作　　者：王伟[1] 王剑 廖专[1] 叶舟[1] 李兆申[1] 

机构地区：[1]第二军医大学附属长海医院消化内科,上海200433 [2]山东省临沂市肿瘤医院放疗科,山东临沂276001

出　　处：《国际内科学杂志》2008年第3期162-166,共5页International Journal of Internal Medicine

摘　　要：丝氨酸蛋白酶抑制剂KazalⅠ型(SPINK1)基因突变的致病机制复杂,众多学者对其在特发性慢性胰腺炎(ICP)中的作用和临床特点进行了深入研究,中日韩在该方面的初步结果与欧美国家有所不同,仍需进一步探讨。The researches on pancreatic secretory trypsin inhibitor（ PSTI）, also known as the serine protease inhibitor Kazal type 1 （SPINK1）, have led to a new way for the pathogenic mechanism of idiopathic chronic pancreatitis （ICP）. The patients with SPINK1 mutation are thought to have a different clinical features from cases without the mutation, Preliminary results in China, Japan and Korea were different from those in Europe and America.

关 键 词：丝氨酸蛋白酶抑制剂Kazal I型 特发性慢性胰腺炎 突变 

分 类 号：R576[医药卫生—消化系统]